Precision medicine & phosphoproteomics - Cooper Rice-Brading Foundation

^a: Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, Australia

^b: School of Women’s and Children’s Health, UNSW Sydney, Sydney, NSW, Australia

^c: University of New South Wales Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia

^d: Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC, Australia

Received 7 March 2021, Revised 9 August 2021, Accepted 9 August 2021, Available online 11 August 2021.

Highlights

• Outcomes for pediatric/AYA sarcoma patients are poor and no targeted treatments exist.

• Pediatric and AYA sarcoma patients rarely harbor actionable genomics aberrations.

• Phosphoproteomics captured novel actionable drivers missed by genomics screens

• Phosphoproteomics explained critical targeted drug mechanism of action/resistance.

• Outcomes in personalized medicine platforms may be enhanced by phosphoproteomics.

Press the link below to read more: